Lundbeck's alcohol dependency drug misses one Phase III endpoint
This article was originally published in Scrip
Executive Summary
As it awaits an EU approval decision for its novel alcohol dependence treatment Selincro (nalmefene), Lundbeck has presented further data on the product, which although positive overall, reveal that one study out of its Phase III programme of three had failed to meet a co-primary endpoint.